Download Center | UCB

This section is intended for media and financial analysts

On Thursday 30th of July, we announced our H1 2026 results. An accompanying webcast for investors and analysts took place at 14:00 CET.

[mp4] UCB Half Year 2026 Earnings Call from UCB on Vimeo

Playing in picture-in-picture

Play

1:14:24

CC/subtitles

Settings

Transcript

QualityAuto

CC/subtitlesOff

Picture-in-Picture

Fullscreen

UCB HY26 Documents

Earning Call Slides

Earnings Call Transcript

Press release

Half Year Report 26 - EN

Half Year Report 26 - FR

Half Year Report 26 - NL

Excel File HY26

Pipeline Overview H1

Facts and Figures HY26

Clinical Trials appendix HY26

UCB FY25 Documents

• Press release
• FY25 Earnings Call - Presentation
• FY25 Earnings Call - Replay
• FY25 Earnings Call - Transcript
• Full Year Report 2025

EMTN Program

Debt Financing

• Retail bonds, due 2023
• EMTN notes, due 2027
• Institutional bonds, due 2028
• Retail bond, due 2029
• Institutional bonds, due 2030

EMTN Prospectus Archive

• EMTN Prospectus 2015
• EMTN Prospectus 2019
• EMTN Prospectus 2021
• EMTN Prospectus 2022
• EMTN Prospectus 2023

### Scientific Presentations, Abstracts, 
Posters, and Publications for Shareholders, Investors, and other Capital Market Participants Only

The following documents are specifically for shareholders, investors, and other capital market participants. The webpages are not intended for members of the general public.

• Bimekizumab
• Rozanolixizumab
• Zilucoplan

Corporate Governance Documents

Also find more information on the dedicated section of our website.

• Governance charter
• Dealing code
• Code of conduct

UCB Reports Archive

Investor Relations Team

Please reach us via investor-relations@ucb.com.